- EN
- JP
Metagen Therapeutics, Inc.
Bringing innovative medicine and pharmaceuticals to life
through cutting-edge microbiome science
News
-
【News】Our Scientific Advisor Shinji Fukuda selected as Highly Cited Researchers of 2024
We are thrilled to announce that Metagen Therapeutics’ Senior Scientific Advisor, Shinji Fukuda was selected a […] -
【Press Release】Juntendo University and Metagen Therapeutics Commences Joint Research on “Fecal Microbiota Transplantation” for Parkinson’s Disease Patients
Juntendo University (Headquaters: Bunkyo-ku, Tokyo; President: Hiroyuki Daida) and Metagen Therapeutics, Inc. […] -
【News】Metagen Therapeutics Selected as Finalist in “Supernova Challenge,” Pitch Competition at GITEX Expand North Star, the World’s Largest Startup Event
Metagen Therapeutics was selected as a finalist in the Supernova Challenge, a pitch competition at GITEX Expan […] -
【Press Release】Start of Fecal Microbiota Transplantation Clinical Study for Esophageal and Gastric Cancer Patients
~Evaluating safety and efficacy of combination therapy with immune checkpoint inhibitors and intestinal microb […] -
【Press Release】Metagen Therapeutics and JSR,Alliance to Establish Microbiome Medicine Investigational Drug Manufacturing Facility
~Scheduled to be operational by end of 2025 for start of clinical trials in Japan and overseas~ Metagen Therap […]
Medical Services・Pipeline/Platform
The human microbiome is comprised of bacterial flora found throughout the human body, including in the intestines, skin, and oral cavity. Intestinal microbiome in particular, has a complex and dynamic population of microorganisms. In recent years, research on the intestinal flora has made significant progress and its symbiotic relationship with various diseases such as cancer, ulcerative colitis, Parkinson’s disease, and allergies, has become clear.
FMT and its research has been shown to be a safe and efficacious treatment around the world, and microbiome drug discovery is being actively carried out.
Founders

Chief Executive Officer
Taku Nakahara Ph.D., MBA

Chief Medical Officer
Dai Ishikawa MD, Ph.D.
Associate Professor
Juntendo University,
Department of Gastroenterology,
Faculty of Medicine


Senior Scientific Advisor
Shinji Fukuda MD, Ph.D.
Project Professor
Keio University,
Institute for Advanced Biosciences


Senior Scientific Advisor
Takuji Yamada Ph.D.
Associate Professor
Tokyo Institute of Technology,
School of Life Science and Technology

腸内細菌療法
メタジェンセラピューティクスはCMO石川が順天堂大学で研究してきた腸内細菌療法の普及を目指します。
Partners



Company
Metagen Therapeutics, Inc. (MGTx)
January 2020
Drug discovery and medical services using microbiome science
President & CEO Taku Nakahara
Director, CMO Dai Ishikawa
Director, CSO Jun Terauchi
Non-Executive Director Tomohiro Anzai
Non-Executive Director Taira Kobayashi
Non-Executive Director Jun Hayashi
Senior Scientific Advisor Shinji Fukuda
Senior Scientific Advisor Takuji Yamada
246-2 Mizukami, Kakuganji, Tsuruoka-city, Yamagata 997-0052 Japan
Toranomon Hills Business Tower 15F
1-17-1 Toranomon, Minato-ku, Tokyo 105-6415 Japan